Lenalidomide and low-dose dexamethasone therapy for Japanese patients with newly diagnosed multiple myeloma: updated results of the MM-025 study

DOI Web Site PubMed
  • ANDO Kiyoshi
    Department of Hematology and Oncology, Tokai University School of Medicine
  • CHOU Takaaki
    Department of Internal Medicine, Niigata Cancer Center Hospital
  • SUZUKI Kenshi
    Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center
  • SHINAGAWA Atsushi
    Department of Hematology, Hitachi General Hospital
  • UCHIDA Toshiki
    Department of Hematology & Oncology, Japanese Red Cross Nagoya Daini Hospital
  • TANIWAKI Masafumi
    Center for Molecular Diagnostics and Therapeutics, Department of Hematology, University Hospital, Kyoto Prefectural University of Medicine
  • HIRATA Hirokazu
    Department of Hematology, Kansai Electric Power Hospital
  • ISHIZAWA Kenichi
    Department of Hematology and Cell Therapy, Yamagata University Faculty of Medicine
  • MATSUE Kosei
    Hematology and Oncology department, Kameda Medical Center
  • OKAMOTO Shinichiro
    Division of Hematology, Department of Internal Medicine, Keio University School of Medicine
  • OTSUKA Maki
    Department of Hematology, National Hospital Organization Kagoshima Medical Center
  • MATSUMOTO Morio
    Department of Hematology, National Hospital Organization Shibukawa Medical Center
  • IIDA Shinsuke
    Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences
  • MATSUMURA Itaru
    Division of Hematology, Department of Internal Medicine, Kinki University Hospital, Faculty of Medicine
  • IKEDA Takashi
    Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center
  • TAKEZAKO Naoki
    Division of Hematology, National Hospital Organization Disaster Medical Center
  • OGAKI Yumi
    Celgene K.K.
  • MIDORIKAWA Shuichi
    Celgene K.K.
  • HOUCK Vanessa
    Celgene Corporation
  • ERVIN-HAYNES Annette
    Celgene Corporation
  • TERUI Yasuhito
    Department of Hematology Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research

Bibliographic Information

Other Title
  • 日本人の未治療多発性骨髄腫患者に対するlenalidomide＋低用量dexamethasone療法 —MM-025試験の最新成績—
  • 臨床研究 日本人の未治療多発性骨髄腫患者に対するlenalidomide +低用量dexamethasone療法 : MM-025試験の最新成績
  • リンショウ ケンキュウ ニホンジン ノ ミチリョウ タハツセイ コツズイシュ カンジャ ニ タイスル lenalidomide +テイヨウリョウ dexamethasone リョウホウ : MM-025 シケン ノ サイシン セイセキ

Search this article

Abstract

<p>In a Japanese phase II study (MM-025), the efficacy and safety of lenalidomide plus low-dose dexamethasone (Rd) were confirmed at a median follow-up of 14.2 months in patients with newly diagnosed multiple myeloma who were ineligible for hematopoietic stem cell transplantation. In the present report, we analyzed the follow-up data from the abovementioned study. Treatment was stopped for all 26 patients after a median follow-up of 31.3 months, and the median treatment duration was approximately 25 months. The overall response rate was 87.5%, and the complete response rate was 20.8%. The median duration of response and progression-free survival were 30.7 and 31.6 months, respectively. The median overall survival has not yet been reached. At least one grade 3/4 adverse event was experienced by 23 patients (88.5%), and 18 patients (69.2%) experienced serious adverse events. There were no treatment-related deaths. Therefore, the efficacy and safety of Rd were confirmed in transplant-ineligible Japanese patients with newly diagnosed multiple myeloma at the present follow-up period.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 58 (11), 2219-2226, 2017

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top